RESEARCH WEEKLY: Barriers to ECT Access for Major Depressive Disorder
By Elizabeth Sinclair Hancq
Electroconvulsive therapy (ECT) is a safe and effective treatment for individuals with severe psychiatric disorders. In fact, ECT has been shown to produce remission rates in individuals with major depressive disorder at rates of 80-90% if used as a first-line treatment. For individuals with treatment-resistant depression, ECT has been shown to produce remission rates in 50-60% of cases, compared to less than 15% when using oral anti-depressive medications. Additionally, ECT has been shown to be effective in individuals with schizophrenia who are treatment-resistant to clozapine, the only antipsychotic medication shown to be effective for treatment-resistant individuals, indicating the effectiveness of the procedure when so many other treatments fail for these individuals.
Despite these promising outcomes, ECT is extremely underutilized. One study conducted in 2015 estimated that just 0.25% of individuals in the United States with major depressive disorder received one or more sessions of ECT. New research published this month in Psychiatric Services from researchers from the Yale Depression Research Program aimed to study barriers to implementation of ECT in order to understand why so few providers offer ECT services.
Implementation barriers to ECT according to practitioners
The study authors first conducted semi-structured qualitative interviews of ECT practitioners to understand key themes around barriers to expanding an existing ECT service or starting a new one. The results from the qualitative interviews informed the creation of a quantitative survey, to which 192 ECT practitioners responded. Medicare data was then used to examine regional variability in ECT services: